Avtor/Urednik		Zwitter, M; Čufer, T; Wein, W
Naslov		Gemcitabine and vincristine: an effective outpatient regimen with low myelotoxicity for stage IV non-small cell lung cancer
Tip		članek
Vir		Neoplasma
Vol. in št.		Letnik 48, št. 3
Leto izdaje		2001
Obseg		str. 200-2
Jezik		eng
Abstrakt		The activity and tolerability of gemcitabine and the non-overlapping toxicity of gemcitabine plus vincristine were the basis for testing this regimen patients with non-small cell cancer (NSCLC). Forty patients (25 male/15 female, median age 52 years) with stage IV NSCLC and a Karnofsky performance status score => 60 entered the trial. Patients received gemcitabine 1000 mg/m2 on days 1,8 and 15 and vincristine 1.4 mg/m2 on days 1 and 15, every 4 weeks. The overall response rate was 16/40 (40%) (N=40); with 2 complete and 14 partial responses; additional 14 patients had minor responses or stable disease. Median duration of remission was 4.5 months, and the median survival was 9 months. In two patients with grade 2 generalized vesicular rash and severe malaise, respectively, treatment-related toxicity led to early termination of treatment. Among patients trated for more two months, vincristine doses werw reduced/omitted for 55% of cycles because of grade 1-2 peripheral neuropathy. Myelotoxicity was frequent but rarely clinically significant. Mean platelet counts on day 1 of cycles 2,3 and 4 were significantly higher than the pre-treatment or post-treatment values. We conclude that vincristine plus gemtabine is an active and well tolerated regimen. Its interesting "platelet-saving" effect doserves further investigation.
Deskriptorji		CARCINOMA, NON-SMALL-CELL LUNG LUNG NEOPLASMS NEOPLASM STAGING DEOXYCYTIDINE VINCRISTINE KARNOFSKY PERFORMANCE STATUS SURVIVAL RATE PLATELET COUNT THROMBOCYTOSIS